It’s time to switch horses and take another look at the evolving bispecific antibody niche with a look at a particularly promising T cell engager in early clinical development, which might offer a few surprises.
We have seen these agents evolve in both hematologic malignancies as well as solid tumours, with a common challenge being CRS events.
What if this side effect could be made more manageable, enabling the agent to do its job on a dual front, namely reinvigorating T cells and reducing some of the hostile immunosuppression dampening down the immune responses?
How about as a potential partner for CAR-T cells to help improve expansion kinetics or in combination with checkpoint blockade so they could work more effectively?
It turns out all this can be done, perhaps in an unconventional and creative fashion…